Akouos, Inc. (AKUS)

NASDAQ: AKUS · IEX Real-Time Price · USD
6.80
+0.04 (0.59%)
At close: Oct 3, 2022 4:00 PM
6.75
-0.05 (-0.74%)
After-hours: Oct 3, 2022 6:23 PM EDT
0.59%
Market Cap 250.92M
Revenue (ttm) n/a
Net Income (ttm) -95.66M
Shares Out 36.90M
EPS (ttm) -2.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 156,044
Open 6.75
Previous Close 6.76
Day's Range 6.63 - 7.08
52-Week Range 2.32 - 11.43
Beta -0.10
Analysts Buy
Price Target 20.91 (+207.5%)
Earnings Date Nov 10, 2022

About AKUS

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibul... [Read more...]

Industry Biotechnology
IPO Date Jun 26, 2020
Employees 103
Stock Exchange NASDAQ
Ticker Symbol AKUS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for AKUS stock is "Buy." The 12-month stock price forecast is 20.91, which is an increase of 207.50% from the latest price.

Price Target
$20.91
(207.50% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Akouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-m...

-The IND for AK-OTOF is the first to receive FDA clearance for a genetic form of hearing loss and the first for an AAV vector therapy with the potential to treat an inner ear condition

2 weeks ago - GlobeNewsWire

Akouos, Inc. (AKUS) Upgraded to Buy: Here's Why

Akouos, Inc. (AKUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago - Zacks Investment Research

Akouos Reports Second Quarter 2022 Financial Results and Provides Business Highlights

BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing...

1 month ago - GlobeNewsWire

Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated ...

- Nonclinical data demonstrate that a single intracochlear administration of an AAVAnc80 vector led to durable restoration of auditory function and was well tolerated, supporting planned clinical develo...

4 months ago - GlobeNewsWire

Akouos Reports First Quarter 2022 Financial Results and Provides Business Highlights

- Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022

4 months ago - GlobeNewsWire

Akouos to Present at Bank of America 2022 Healthcare Conference

BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabli...

4 months ago - GlobeNewsWire

Akouos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

- Advanced toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022

6 months ago - GlobeNewsWire

Akouos to Participate in Upcoming March Virtual Investor Conferences

BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disab...

6 months ago - GlobeNewsWire

Akouos Presents Nonclinical Data Demonstrating Potential Applicability of Precision Genetic Medicine Platform for a B...

- Data from two nonclinical studies evaluating protein expression and tolerability support future clinical development of AK-antiVEGF for the treatment of vestibular schwannoma

7 months ago - GlobeNewsWire

Akouos to Present at the Association for Research in Otolaryngology 45th Annual Mid-Winter Meeting

BOSTON, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing...

8 months ago - GlobeNewsWire

Akouos Reports Third Quarter 2021 Financial Results and Provides Business Highlights

- Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022

10 months ago - GlobeNewsWire

Akouos Appoints Stacy Price as Chief Technical Officer

BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing...

11 months ago - GlobeNewsWire

Akouos to Present at Jefferies Gene Therapy/Editing Summit

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabl...

11 months ago - GlobeNewsWire

Akouos to Present at Upcoming September Virtual Investor Conferences

BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disab...

1 year ago - GlobeNewsWire

Akouos Reports Second Quarter 2021 Financial Results and Provides Business Highlights

- Announced European Commission designation of AK-OTOF as an orphan drug for the treatment of otoferlin gene-mediated hearing loss

1 year ago - GlobeNewsWire

Akouos' Hearing Loss Gene Therapy Poised To Receive Orphan Drug Tag In Europe

The European Medicines Agency (EMA) Committee for Orphan Medicinal Products has issued a positive opinion on Akouos Inc's (NASDAQ: AKUS) application for orphan drug designation for AK-OTOF. AK-OTOF is a...

1 year ago - Benzinga

Akouos to Present at Upcoming August Virtual Investor Conferences

BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabl...

1 year ago - GlobeNewsWire

Akouos Reports First Quarter 2021 Financial Results and Provides Business Updates

- Leadership team expanded with appointment of Kathy Reape, M.D. as chief development officer

1 year ago - GlobeNewsWire

Akouos Presents Nonclinical Data Supporting Future Clinical Development of AK-OTOF and AK-antiVEGF at the American So...

- Intracochlear delivery of a dual AAVAnc80 vector encoding human otoferlin results in full-length protein expression in inner hair cells of non-human primates and in durable protein expression sufficie...

1 year ago - GlobeNewsWire

Akouos to Present at Bank of America 2021 Virtual Healthcare Conference

BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabli...

1 year ago - GlobeNewsWire

Akouos Appoints Dr. Kathy Reape as Chief Development Officer

BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing ...

1 year ago - GlobeNewsWire

Akouos to Present Nonclinical Data from AK-OTOF and AK-antiVEGF Programs at the American Society of Gene and Cell The...

BOSTON, April 27, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearin...

1 year ago - GlobeNewsWire

What Makes Akouos, Inc. (AKUS) a New Buy Stock

Akouos, Inc. (AKUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

Akouos Receives Orphan Drug and Rare Pediatric Disease Designations for AK-OTOF for the Treatment of Otoferlin Gene-M...

BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearin...

1 year ago - GlobeNewsWire

Akouos to Present at 20th Annual Needham Virtual Healthcare Conference

BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disab...

1 year ago - GlobeNewsWire